Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. | Director | Common Stock | 28.7K | $36.2K | $1.26 | Jun 1, 2024 | Direct |
Aclaris Therapeutics, Inc. | Director | Restricted Stock Units | 0 | $0 | $1.26 | Jun 1, 2024 | Direct |
Societal CDMO, Inc. | Director | Common Stock | 0 | $0 | $1.10 | Apr 8, 2024 | Direct |
Mallinckrodt plc | EVP & CFO | Restricted Stock Units | 20.5K | Feb 2, 2024 | Direct | ||
Aclaris Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 15.8K | Jun 1, 2023 | Direct | ||
Mallinckrodt plc | EVP & CFO | Ordinary Shares | 0 | $37.50 | Nov 14, 2023 | Direct | |
Societal CDMO, Inc. | Director | Stock Option (Right to Buy) | 0 | Apr 8, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ACRS | Aclaris Therapeutics, Inc. | Jun 1, 2024 | 2 | $0 | 4 | Jun 4, 2024 | Director |
SCTL | Societal CDMO, Inc. | Apr 8, 2024 | 4 | -$320K | 4 | Apr 8, 2024 | Director |
NONE | Mallinckrodt plc | Feb 2, 2024 | 1 | $0 | 4 | Feb 6, 2024 | EVP & CFO |
MNKTQ | Mallinckrodt plc | Nov 14, 2023 | 1 | $0 | 4 | Nov 16, 2023 | EVP & CFO |
SCTL | Societal CDMO, Inc. | Aug 28, 2023 | 1 | $25K | 4 | Aug 28, 2023 | Director |
MNK | Mallinckrodt plc | Aug 17, 2023 | 1 | -$11.1K | 4 | Aug 18, 2023 | EVP & CFO |
MNK | Mallinckrodt plc | Jun 30, 2023 | 1 | $0 | 4 | Jul 5, 2023 | EVP & CFO |
ACRS | Aclaris Therapeutics, Inc. | Jun 1, 2023 | 4 | $0 | 4 | Jun 5, 2023 | Director |
SCTL | Societal CDMO, Inc. | May 17, 2023 | 2 | $0 | 4 | May 19, 2023 | Director |
MNK | Mallinckrodt plc | Apr 3, 2023 | 1 | $0 | 4 | Apr 5, 2023 | EVP & CFO |
MNK | Mallinckrodt plc | Dec 14, 2022 | 1 | $0 | 4 | Dec 22, 2022 | EVP & CFO |
MNKPF | Mallinckrodt plc | Jun 16, 2022 | 2 | $0 | 4 | Jun 21, 2022 | EVP & CFO |
ACRS | Aclaris Therapeutics, Inc. | Jun 2, 2022 | 4 | $0 | 4 | Jun 6, 2022 | Director |
SCTL | Societal CDMO, Inc. | May 18, 2022 | 2 | $0 | 4 | May 20, 2022 | Director |
ACRS | Aclaris Therapeutics, Inc. | Jun 3, 2021 | 2 | $0 | 4 | Jun 4, 2021 | Director |
SCTL | Recro Pharma, Inc. | Apr 20, 2021 | 1 | $0 | 4/A | May 17, 2021 | Director |